Authum Investment & Infrastructure Ltd, Century Plyboards (India) Ltd, Tanla Platforms Ltd and Amber Enterprises India Ltd are among the other gainers in the BSE's 'A' group today, 01 January 2025.Strides Pharma Science Ltd surged 10.27% to Rs 727.55 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 1.32 lakh shares were traded on the counter so far as against the average daily volumes of 78858 shares in the past one month. Authum Investment & Infrastructure Ltd spiked 9.59% to Rs 1867.15. The stock was the second biggest gainer in 'A' group. On the BSE, 6551 shares were traded on the counter so far as against the average daily volumes of 8287 shares in the past one month. Century Plyboards (India) Ltd soared 9.46% to Rs 808. The stock was the third biggest gainer in 'A' group. On the BSE, 67435 shares were traded on the counter so far as against the average daily volumes of 8175 shares in the past one month. Tanla Platforms Ltd exploded 9.29% to Rs 734.45. The stock was the fourth biggest gainer in 'A' group. On the BSE, 68543 shares were traded on the counter so far as against the average daily volumes of 46356 shares in the past one month. Amber Enterprises India Ltd added 6.08% to Rs 7844. The stock was the fifth biggest gainer in 'A' group. On the BSE, 24875 shares were traded on the counter so far as against the average daily volumes of 40408 shares in the past one month. Powered by Capital Market - Live

CARE Ratings Ltd, Avalon Technologies Ltd, Adani Green Energy Ltd and Easy Trip Planners Ltd are among the other losers in the BSE's 'A' group today, 04 December 2024.Strides Pharma Science Ltd lost 5.11% to Rs 1513.1 at 14:47 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 34509 shares were traded on the counter so far as against the average daily volumes of 30958 shares in the past one month.CARE Ratings Ltd crashed 4.56% to Rs 1430. The stock was the second biggest loser in 'A' group.On the BSE, 4186 shares were traded on the counter so far as against the average daily volumes of 11904 shares in the past one month.Avalon Technologies Ltd tumbled 4.55% to Rs 875. The stock was the third biggest loser in 'A' group.On the BSE, 53104 shares were traded on the counter so far as against the average daily volumes of 1.01 lakh shares in the past one month.Adani Green Energy Ltd dropped 3.66% to Rs 1264.35. The stock was the fourth biggest loser in 'A' group.On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Easy Trip Planners Ltd corrected 3.53% to Rs 16.38. The stock was the fifth biggest loser in 'A' group.On the BSE, 52.31 lakh shares were traded on the counter so far as against the average daily volumes of 23.43 lakh shares in the past one month.Powered by Capital Market - Live

Strides Pharma Science has allotted 2,04,500 equity shares under ESOP. Consequent to above, the paid-up share capital of the Company has increased from Rs. 91,95,82,140 consisting of 9,19,58,214 equity shares of Rs. 10/- each to 92,16,27,140 consisting of 9,21,62,714 equity shares of Rs. 10/- each. Powered by Capital Market - Live

Strides Pharma Science has fixed 06 December 2024 as record date for r determining names of the equity shareholders of Strides who shall be entitled for allotment of equity shares by OneSource, as consideration under the scheme of arrangement. Powered by Capital Market - Live

Strides Pharma Science announced that its associate company, OneSource Specialty Pharma has successfully completed the fundraise activity and has allotted equity shares to the marquee domestic and international investors who participated in this issue. OneSource Specialty Pharma has allotted 6,277,909 fully paid up equity shares at a price of Rs 1,276/- (including a premium of Rs 1,275/-) per share on a private placement basis to marquee domestic and international investors. The total consideration received from the allotment stands at Rs 801 crore, valuing OneSource at a pre-money equity valuation of USD 1.65 billion. This milestone reinforces OneSource's strong positioning as India's first specialty pharma CDMO and its readiness for robust growth ahead of its proposed listing. Powered by Capital Market - Live

Strides Pharma Science has received a significant boost with the National Company Law Tribunal (NCLT) approving the scheme of arrangement for the creation of OneSource Specialty Pharma. This decision paves the way for India's first specialty pharma Contract Development and Manufacturing Organization (CDMO). The creation of OneSource brings together the specialized businesses of Strides, Steriscience and the high-end biologics CDMO business from OneSource (formerly Stelis Biopharma). This integration, underpinned by a recently secured equity commitment of Rs 801 crore ($95 million) from a group of renowned investors, at a pre-money equity valuation of $1.65 billion, positions OneSource for robust growth, Strides Pharma Science said in a statement. Following NCLT approval, OneSource is set to list its equity shares on the BSE and NSE, subject to regulatory clearances. Strides shareholders will receive one OneSource equity share for every two Strides shares held. The demerged undertakings from Strides and Steriscience will be vested with OneSource effective 1 April 2024. Effective date of de-merger shall be communicated to the stock exchanges in due course. This strategic move is expected to unlock value for Strides' stakeholders. Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. It reported a consolidated net profit of Rs 93.23 crore in Q1 FY25 as against a net loss of Rs 131.34 crore posted in Q2 FY24. Revenue from operations stood at Rs 1201.1 crore in the quarter ended September 2024, registering a growth of 20.17% from Rs 999.43 crore posted in the quarter ended September 2023. Powered by Capital Market - Live

Strides Pharma Global, Singapore (SPG), a wholly owned step-down subsidiary of Strides Pharma Science, is acquiring balance stake in Strides Pharma International AG (formerly Fairmed Healthcare AG) (Strides Switzerland), a step-down subsidiary of the Company for an aggregate consideration of ~CHF 1.01 million. SPG currently owns 70% stake in Strides Switzerland. As part of business consolidation and to achieve operational synergy, SPG is acquiring the balance 30% stake in Strides Switzerland. Strides Switzerland is strategically positioned to serve key markets in Europe. The acquisition marks a significant milestone in Strides' expansion efforts, further strengthening its position in the region. The business is led by  Oren Weininger, who is the longstanding CEO of Strides Switzerland. Oren shall continue to lead the business in this region. His wealth of experience and expertise will drive company's continued success and growth in the European market.Powered by Capital Market - Live

Net profit of Strides Pharma Science reported to Rs 93.23 crore in the quarter ended September 2024 as against net loss of Rs 131.34 crore during the previous quarter ended September 2023. Sales rose 20.18% to Rs 1201.11 crore in the quarter ended September 2024 as against Rs 999.43 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1201.11999.43 20 OPM %18.5711.09 - PBDT169.2668.14 148 PBT118.738.03 1379 NP93.23-131.34 LP Powered by Capital Market - Live

Revenue from operations stood at Rs 1201.1 crore in the quarter ended September 2024, registering a growth of 20.17% from Rs 999.43 crore posted in the quarter ended September 2023. Profit before exceptional items and tax was at Rs 131.54 crore in Q2 FY25, zoomed 161.61% from Rs 50.28 crore recorded in Q2 FY24. The company reported an exceptional loss of Rs 3.87 crore during the quarter. The firm reported quarterly EBITDA of Rs 235.80 crore in Q2 FY25, registering a growth of 30.92% year on year. EBITDA margin improved to 19.6% in Q2 FY25 as compared to 17.5% recorded in the corresponding quarter previous year. Gross margin grew by 15.6% YoY to Rs 703.20 crore during the quarter. Gross margin reduced by 72bps YoY to 58.5% in the quarter ended September 2024. US revenues at a historic high of $75m in Q2 FY25, grew 26.2% YoY. The company said that The US business poised to achieve the approximately $400million objective by FY27-28, reaffirming FY25 revenue outlook of $285million - $300million. Arun Kumar, founder & executive chairperson, and Badree Komandur, MD & group CEO, 'We continue to deliver on the momentum built over several preceding quarters and delivered another strong quarter. Q2FY25 demonstrated sustained growth across all markets fueled by new product launches. US operations reported highest ever quarterly revenue of $75m in Q2FY25. Strong Y-o-Y improvement in absolute EBITDA and EBITDA margin reflects our continued focus on operational efficiency and profitability.' Strides Pharma Science is engaged in develops and manufactures a wide range of IP-led niche pharmaceutical products. Shares of Strides Pharma Science shed 0.15% to currently trade at Rs 1551.30 on the BSE. Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live